17 March 2016 09:30-16:30, London, United Kingdom

In silico tools can rapidly profile large data sets without the need for analytical testing. It is this predictivity, allied to the significant time and resource savings that make these tools so attractive within pharmaceutical research and development. Within discovery there has been significant effort to develop more ‘drug like’ molecules. This involves enhancing both the physiochemical and biopharmaceutical properties. In silico tools have been widely used to enhance solubility and permeability. PBPK modelling also supports formulation efforts to optimise in vivo exposure.
Modelling has also been used to optimise the manufacturability of prototype formulations and their supporting processes. In silico tools can rapidly screen real and potential impurities and degradants for mutagenicity, as well as their ‘purgability’ from the synthetic route. In silico tools are used to identify the degradation pathways and optimise the resultant shelf-life. This symposium brings leading experts to give solutions to the big issues, advice, best practice and current developments.

  • Dr Darren GreenGSK, United Kingdom
  • Sue Cole, Pharmacokinetics Assessor, MHRAPharmacokinetics Assessor, MHRA, United Kingdom
  • Dr Kendal PittGSK, United Kingdom
  • Dr Alex HardingLhasa, United Kingdom
  • Dr Andy TeasdaleAZ, United Kingdom
Sponsorship & supporting organisations: Academy of Pharmaceutical Sciences
Venue: The Science Room, The Royal Society of Chemistry, Burlington House, London, United Kingdom
Organised by Joint Pharmaceutical Analysis Group